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Abstract
Peptidylarginine Deiminases (PADs) convert arginine residues on substrate proteins to citrulline. Previous reports have
documented that PAD2 expression and activity varies across the estrous cycle in the rodent uterus and pituitary gland,
however, the expression and function of PAD2 in mammary tissue has not been previously reported. To gain more insight
into potential reproductive roles for PAD2, in this study we evaluated PAD2 expression and localization throughout the
estrous cycle in canine mammary tissue and then identified possible PAD2 enzymatic targets. Immunohistochemical and
immunofluorescence analysis found PAD2 expression is low in anestrus, limited to a distinct, yet sparse, subset of epithelial
cells within ductal alveoli during estrus/early diestrus, and encompasses the entire epithelium of the mammary duct in late
diestrus. At the subcellular level, PAD2 is expressed in the cytoplasm, and to a lesser extent, the nucleus of these epithelial
cells. Surprisingly, stimulation of canine mammary tumor cells (CMT25) shows that EGF, but not estrogen or progesterone,
upregulates PAD2 transcription and translation suggesting EGF regulation of PAD2 and possibly citrullination in vivo. To
identify potential PAD2 targets, anti-pan citrulline western blots were performed and results showed that citrullination
activity is limited to diestrus with histones appearing to represent major enzymatic targets. Use of site-specific anti-
citrullinated histone antibodies found that the N-terminus of histone H3, but not H4, appears to be the primary target of
PAD activity in mammary epithelium. This observation supports the hypothesis that PAD2 may play a regulatory role in the
expression of lactation related genes via histone citrullination during diestrus.
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Introduction
The peptidylarginine deiminases (PADs) are a family of calcium-
dependent enzymes that post-translationally convert arginine
residues on substrate proteins to the non-standard amino acid
citrulline. PAD catalyzed citrullination, with concomitant loss of the
positive imine group, converts the strongly basic arginine residue to
a neutral amino acid. Loss of basic charge caused by citrullination is
thought to disrupt charge distribution within the substrate protein
and alter its ability to interact with other molecules [1,2]. The PAD
family consists of five members (1–4 and 6) located within a gene
cluster encompassing ,300 kb at human chromosome 1p36.13.
PADs 1 and 3 and PADs 4 and 6, respectively, are closely aligned
[1,3] while PAD2, the apparent ancestral homolog, is set apart from
the other PADs on chromosome 1 and is oriented in the opposite
direction. Additionally, PAD2 is the most widely expressed and
largest of the PAD genes with a long, distinctive 39 untranslated
region (UTR). The PAD enzymes and citrullinated proteins are
associated with multiple human diseases including rheumatoid
arthritis, multiple sclerosis, Alzheimer’s disease, and, more recently,
with cancer [4–7].
PAD expression in mammary tissue has not been documented.
However, previous reports have shown that PAD2 is expressed in
other reproductive tissues in a hormone dependent manner. For
example, both PAD2 and citrullination levels were found to be
higher in the female rodent pituitary gland than in males and
PAD2 was also found to be expressed in the luminal and glandular
epithelia of the uterine endometrium with expression levels
changing in an estrous cycle-dependent manner [8,9]. Further,
ovariectomized mice treated with estrogen (E2) displayed both
increased PAD2 mRNA levels and increased citrullination in
uterine samples compared to vehicle treated controls suggesting
E2-mediated regulation.
Potential PAD2 targets in reproductive tissues have not been
previously identified. However, two in vivo substrates for PAD2
have been described in other tissues: myelin basic protein (MBP) in
neurons and vimentin in skeletal muscle and macrophages. In
macrophages, the presence of high calcium levels cause PAD2 to
citrullinate vimentin resulting in the breakdown of the vimentin
intermediate filament network potentially to play a role in
apoptotic events [10]. The brain expresses PAD2 where it
citrullinates MBP a major component of the myelin sheath that
covers the axons of nerves. MBP normally contains non-
citrullinated arginine residues allowing compact myelin sheaths
to form; citrullinated MBP is not capable of forming tight sheaths
which is hypothesized to lead to neurodegeneration and possibly
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can citrullinate arginine residues on histone H4 [12]. When
incubated with histones, purified skeletal muscle PAD2 converts
methyl arginine 3 histone H4 to citrulline, although no evidence
yet exists to link PAD2 to histone citrullination in vivo.
A complete understanding of the role of PAD2 in vivo requires
the utilization of animal models to follow PAD2 expression
through hormonal fluctuations across the entire estrous cycle.
Compared to mice, the dog mammary gland model is more closely
in line with human breast tissue from a molecular, morphological,
and hormonal prospective [13]. For example, during the estrous/
menstrual cycle hormonal fluctuations in dog and human females
show similar dramatic rises in E2 and progesterone (P4). Both
female dogs and humans also show significant changes in
mammary stromal tissue during the estrous cycle that does not
occur in mice [14,15]. Additionally, the dog is a suitable model for
evaluation of estrous cycle and lactation-dependant mammary
changes considering dogs facilitate full lactational capabilities
regardless of parturition with each cycle. This difference may be
due to a species’ dependant persistent elevation of P4 throughout
diestrus leading to a pseudopregnant state [14]. Therefore, here
we have utilized canine mammary tissue to examine how and
where PAD2 is expressed and the functional consequences of
expression.
In this report, we show for the first time that PAD2 is expressed
in the cytoplasm and nucleus of canine mammary alveolar luminal
epithelial cells. Further, we show that PAD2 expression varies
across the estrous cycle, with expression initiating during
mammary gland proliferation in estrus/early diestrus and
increasing through lactation during diestrus. Additionally, we
show that PAD2 expression at diestrus directly correlates with
citrullination of the histone H3 tail in mammary epithelial cells
suggesting that PAD2 may play a novel role in gene regulation in
the mammary gland.
Materials and Methods
Materials
Canine mammary tissue samples were collected from 6 dogs (2
in anestrus, 2 in estrus/early diestrus and 2 in late diestrus based
on tissue morphologic changes) immediately after euthanasia in
accordance with the guidelines outlined in the Report of the
AVMA on Euthanasia under a Cornell University approved
IACUC protocol (#2007-0073). Authors did not house the
animals but collected tissues from intact female beagles between
3 and 5 years old which were being used for a different study as
part of a collective effort to utilize all available tissues and decrease
the number of animals used. Mammary tissue sections were snap
frozen and stored at 280uC until utilized for protein and RNA
experiments detailed below. At the same time, additional
mammary tissue sections were placed in neutral buffered formalin
and allowed to fix overnight. The following morning fixed
mammary tissue was embedded, sectioned, and floated on
micro-probe slides by the Cornell University Histology Core
Laboratory. All canine mammary tissues were evaluated by a
veterinary pathologist for stage of the estrus cycle, immunostaining
and general morphology.
Canine mammary tumor 25 (CMT25) cells were acquired from
the Cornell University comparative oncology program and grown
in phenol red free RPMI 1640 (Invitrogen, Carlsbad, CA)
supplemented with charcoal stripped 10% fetal bovine serum
(FBS) (Invitrogen), 1% sodium pyruvate (Invitrogen), 1% HEPES
buffer (Invitrogen), 1% sodium bicarbonate (Sigma-Aldrich,
St.Louis, MO) and 1% antibiotic antimycotic (Sigma-Aldrich)
[16]. For experiments, the cells were cultured in RPMI 1640 with
1% FBS for 24 hours and then treated with either 100 ng/ml of
human epidermal growth factor (Invitrogen), 150 ng of sheep
prolactin (Sigma-Aldrich) or 100 nM E2 (Sigma-Aldrich) or P4
(Sigma-Aldrich) for 24 hours and then harvested.
Immunohistochemistry (IHC) and immunofluorescence
(IF)
IHC and IF experiments were carried out using a standard
protocol. Briefly, slides were rehydrated in 3X 5 minute washes in
xylene followed by single sequential 5 minute washes in 100, 95,
and 75% EtOH. Slides for IHC were then incubated for 10
minutes in 0.5% hydrogen peroxide in methanol to quench
endogenous peroxidases, however this step was omitted for IF
slides. Next, slides were submerged in 0.01 M sodium citrate and
boiled 2X for 10 minutes to retrieve antigens. After cooling, slides
were washed in 1X PBS and then blocked in 10% normal goat
serum and 2X casein (Vector Labs, Burlingame, CA) for 20
minutes at room temperature in a humidified microprobe
chamber. Next, slides were blotted to remove excess blocking
solution and then primary antibody diluted in 1X PBS was added
for 2 hours at room temperature. Antibody dilutions are as
follows: anti-PAD2 (ProteinTech #122100-1-AP, Chicago, IL)
1:100, anti-Cytokeratin (Dako MS3515, Carpinteria, CA) 1:100,
anti-p63 (NeoMarkers MS-1084-P, Fremont, CA) 1:100, anti-
Ki67 (Biogenex Labs BGX-Ki67, San Ramon, CA) 1:50,
biotinylated WGA (Vector Labs, B-1025), anti-pan-citrulline
(Millipore 17-347, Billerica, MA) 1:50. After washing three times,
slides were incubated with a secondary antibody (biotinylated
secondary for PAD2) diluted 1:200 in 1X PBS for 1 hour at room
temperature then washed 3X in PBS. IHC slides were incubated
in DAB chromagen (Vector Labs) solutions according to the
manufacturer’s protocol, washed and then counterstained with
hematoxylin and coverslip mounted. IF slides were incubated in
avidin conjugated-FITC (Vector Labs), washed and then mounted
using Vectashield containing DAPI (Vector Labs). IHC and IF for
pan-citrulline require an additional step after antigen retrieval due
to the necessity of chemical modification of citrulline residue for
antibody recognition. Slides were incubated in acid solution
overnight at 37uC to modify the citrulline residues according to the
manufacturer’s protocol (Millipore). The following morning, slides
were rinsed in ddH2O 3X before proceeding to the blocking step
described above. During each experiment, duplicate slides were
treated with control rabbit IgG antibody at the appropriate
concentrations as a negative control.
Western blotting
Homogenized mammary tissue and CMT25 cells were lysed in
RIPA buffer containing 20 mM Tris (pH 8.0), 137 mM NaCl,
10% glycerol, 1% NP-40, 0.1% SDS, 0.5% deoxycholate, and
0.2 mM PMSF and 1X general protease inhibitor. Protein
concentration in lysates was determined by Bradford assay prior
to gel loading to ensure equal protein loading. 6X sample buffer
(300 mM Tris-HCl, pH 6.8, 60% glycerol, 30 mM DTT, 6%
SDS) was added to yield a final concentration of 1X and lysates
were boiled at 95uC for 5 min. Samples were subjected to SDS
polyacrylamide gel electrophoresis on a 10 or 15% gel (acrylami-
de:bis-acrylamide ratio of 29:1) and electro-blotted to Immobilin
PVDF membranes (Millipore). Membranes were blocked in 1X
casein diluted in Tris buffered saline (TBS). Anti-PAD2 (Protein-
Tech), H3cit 2-8-17 (Abcam ab77164, Cambridge, MA), H3cit 26
(Abcam ab19847), H4cit 3 (Millipore 07-596), and Histone 3
antibody (Upstate 05-499) were diluted 1:1000 and incubated
overnight at 4uC. Blots were washed and then incubated with a
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(Jackson ImmunoResearch Labs, West Grove, PA) for 2 hr at
room temperature. All blots were washed for 60 min (6610 min)
with TBS-Tween after secondary antibody and then visualized by
chemiluminescence using Millipore Immobilon Western. To
confirm equal protein loading, membranes were stripped and re-
probed with anti-b-actin (Abcam ab8227) or anti-cytokeratin
(Dako) diluted 1:2000. Western blots for pan-citrulline were
electrophoresed and transferred according to standard protocols,
however prior to blocking, membranes were subject to an
overnight acid treatment at 37uC to chemically modify the
citrulline residues according to the manufacturer’s protocol
(Millipore). The following morning, membranes were washed in
ddH2O three times and then blocked and probed with the pan-
citrulline antibody (1:1000). Densitometry measurements were
obtained from three independent western blots and measured
using the BioRad Versdoc 4000. All treatment groups are
compared to vehicle treated control in each experiment.
qPCR
Three independent samples of frozen canine mammary tissue
from each of the three estrus cycle stages were cut in .0.5 cm
sections and placed in RNAlater-Ice (Ambion, Austin, TX) for
24 hours to help stabilize the mRNA. After 24 hours, tissue was
transferred to a new tube containing Qiagen RLT lysis buffer and
homogenized (Qiagen, Valencia, CA). Messenger RNA was
purified according to the Qiagen RNeasy protocol including on
column DNAse treatment to remove genomic DNA. The resulting
mRNA purified from canine mammary tissue was quantified and
0.5 mgs reverse transcribed using ABI High Capacity RNA to
cDNA kit according to manufacturer’s protocol (ABI, Foster City,
CA). Complementary DNA was subject to qPCR analysis with
intron spanning primers specific for the 75 kDa isoform of PAD2
(FWD 59-TGAGAGCCTCGTGCAAGAGAACC-39 and REV
59-CGTGAGCCCCAACTCCTTCTTG-39). Ribosomal protein
S5 (RPS5) is a validated canine reference gene and was used as our
endogenous control for qPCR analysis (FWD 59-TCACTGGT-
GAGAACCCCCT-39 and REV 59-CCTGATTCACACGGCG-
TAG-39) [17]. Quantitative PCR data was analyzed by the delta/
delta Ct method in which all PAD2 Ct values are adjusted to
corresponding RPS5 levels. For estrus cycle stage and hormone/
growth factor treatment comparisons, the anestrus or vehicle
treated control samples are normalized to 1 and all values are
expressed as the mean 6 SEM.
Statistical Analysis
All experiments were independently repeated at least three
times. Values were expressed as the mean 6 the SEM. Means
were separated by one-way ANOVA using Tukey’s HSD and
P,0.05 was considered statistically significant.
Results
Canine PAD2 is expressed in the mammary gland and its
expression varies in an estrous cycle-dependent manner
Canine mammary tissue undergoes pronounced morphological
rearrangement over the course of the estrous cycle. Although
hormonal changes clearly facilitate this dramatic reorganization,
the downstream mechanisms by which these hormones carry out
this transformation remain unclear.
To begin investigating the possibility that PAD2 may play a role
in these reorganization events, we obtained mammary tissue from
naturally cycling beagles. Mammary tissue sections were staged by
a veterinary pathologist using morphological criteria as described
in a recent review article [18] and were classified as being in one of
three stages: anestrus (showing involution), estrus/early diestrus
(showing edema, and stromal and epithelial proliferation) or late
diestrus (showing active lactation).
Canine mammary tissue at anestrus displayed limited poorly
differentiated nests of epithelium and this epithelium showed weak
PAD2 staining (Figure 1A a–b). Interestingly, mammary tissue in
estrus/early diestrus showed characteristic alveolar proliferation as
confirmed with Ki67 staining (Figure 1B). PAD2 staining in this
stage is sparse and primarily localized to the scattered expanding
end terminal alveolar units (Figure 1A c–d, arrow). However, by
diestrus when mammary ducts are well differentiated, PAD2
expression was present in all the alveolar units and this signal was
not detected in either ductules or ducts (Figure 1A e–f, arrow). In
stark contrast, PAD4 IHC staining of canine mammary tissue
sections indicate that PAD4 staining is lowest during late diestrus
supporting the hypothesis of a unique role for PAD2 during late
diestrus (Figure S1B).
To confirm staging of late diestrus samples and milk production,
we co-stained our tissues with wheat germ agglutin (WGA), which
stains the apical membrane of actively lactating mammary glands.
Results showed that PAD2 expression also strongly correlates with
WGA staining at diestrus, thus potentially linking PAD2
expression with lactation (Figure 1B). Finally, we used TUNEL
staining to determine if any of our estrous cycle staged mammary
tissue samples show high levels of apoptosis as occurs during
mammary gland involution. None of our samples showed a high
degree of apoptosis/necrosis indicating that the tissues were not
actively involuting; however the anestrus sections did display the
most apoptotic cells (data not shown). Thus, by both morpholog-
ical and cellular IF labeling, PAD2 expression varies over the
course of the canine estrous cycle with highest expression levels
appearing in alveolar unit epithelium during diestrus.
Since we demonstrate that PAD2 is expressed in mammary
tissue, we next sought to define which cell types express PAD2
during the different phases of the canine estrous cycle. To
accomplish this objective, we used IF microscopy on the same
tissue sections utilized in the IHC experiments. To label and
visualize specific cell populations within the mammary tissue we
used antibodies specific for PAD2, cytokeratin (an epithelial
marker), p63 (a myoepithelial marker) [19], or DAPI (nuclear
stain). Regarding PAD2 tissue localization, results showed that,
similar to cytokeratin, PAD2 is primarily expressed in epithelial
cells. Co-staining with the anti-p63 antibody was then carried out
to investigate if PAD2 primarily localized to myoepithelial or
luminal epithelial cells. Results showed that PAD2 expression does
not overlap with myoepithelial p63 positive cells and is thus mainly
confined to mammary luminal epithelial cell populations
(Figure 1C).
PAD2 mRNA and protein levels are highest during canine
diestrus
We next examined PAD2 mRNA and protein levels from the
same staged tissue extracts by qPCR and western blot in an effort
to corroborate our IHC findings. Intron spanning primers specific
to the catalytically active 75 kDa isoform of PAD2 were used to
detect PAD2 mRNA and expression was normalized to a well
characterized canine reference gene, RPS5 [17]. Messenger RNA
levels were seen to significantly increase approximately 1 fold
from anestrus to estrus with an additional fold increase being
observed from estrus to diestrus (P,0.01) (Figure 2A). In
concordance with our IHC and qPCR analysis, staged mammary
tissue protein samples were examined by SDS-PAGE and
confirmed that PAD2 expression is highest in late diestrus
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IHC and western blot experiments is specific for the 75 kDa
isoform of PAD2 and does not appear to cross-react with other
PAD family members (Figure S2).
PAD2 expression is induced by EGF in the Canine
Mammary Tumor (CMT) 25 primary mammary carcinoma
epithelial cell line
Given the observed estrous cycle dependant changes in
expression of PAD2 in canine mammary tissue samples, we
decided to directly test the hypothesis that PAD2 expression is
regulated by specific hormones and/or growth factors in
mammary epithelial cells. Thus, we examined the effect of
hormones and growth factors such as E2, EGF, prolactin and P4
on PAD2 expression in canine mammary epithelial cells using two
canine mammary tumor-derived cell lines: CMT12 and CMT25
cells [16,20]. Preliminary experiments found that PAD2 was only
expressed in the CMT25 cell line, indicating differential regulation
of PAD2 expression across these two cell lines (data not shown).
Our analysis of the CMT25 cells, however, found that this line
constitutively expressed PAD2 in the presence of low serum levels.
Given estrous cycle dependent changes in PAD2 expression, we
predicted that E2,P 4, or prolactin would potentially induce PAD2
expression. Surprisingly, however, treatment of CMT25 cells with
these hormones did not significantly alter PAD2 expression with
the exception of cells treated with EGF, where PAD2 expression
was significantly increased (P,0.01) (Figure 3A). Further exam-
ination of PAD2 expression by qPCR of hormone/growth factor
treated cells confirmed that PAD2 transcription was only affected
by EGF stimulation (P,0.05) (Figure 3B). Presently, the specific
signal transduction pathway responsible for EGF induced
expression of PAD2 is under investigation.
PAD2 is expressed in both the cytoplasmic and nuclear
compartment of mammary epithelial cells
Interestingly, initial IHC and IF studies suggested that a fraction
of PAD2 localized to the nucleus. To further investigate the
subcellular localization of PAD2, mammary tissue sections were
evaluated by IF, and high magnification images were taken.
Results show that in diestrus samples, PAD2 can be visualized as
punctate foci in euchromatic (i.e. nuclear regions that are stained
poorly by DAPI) regions of the nucleus suggesting that PAD2
enzymatic targets may be nuclear in nature (Figure 4A, arrows).
While a role for PAD2 in nuclear function has not been previously
described, reports have shown that PAD2 can target histones for
citrullination in vitro [12].
Figure 1. PAD2 expression in canine mammary tissue. (A) PAD2 is expressed in the canine mammary gland in an estrous cycle dependant
fashion with the highest expression in alveolar unit epithelium during late diestrus. Anestrus (a 2006, b 6306), estrus/early diestrus (c 2006, d 6306),
and late diestrus (e 2006, f 6306) mammary tissue sections were probed with anti-PAD2 antibody or equal concentration of rabbit IgG as a control
(see Supplemental Figure 1A) and counterstained with hematoxylin. Arrow in estrus/early diestrus depicts occasional alveolar end units expressing
PAD2. Arrow in diestrus depicts lack of PAD2 epithelial staining in ductule. (B) PAD2 (green fluorescent signal) is first detected in estrus/early diestrus,
a time of high cellular proliferation, but PAD2 is widely expressed in late diestrus during active lactation. In estrus the red fluorescent signal
represents the proliferation marker Ki67 (4006), while in diestrus the red fluorescent signal is WGA (4006) which stains the apical membrane of
actively lactating mammary glands and all nuclei are stained with DAPI. (C) PAD2 expression is restricted to canine mammary luminal epithelial cells.
PAD2 expression is shown as green fluorescent signal during anestrus and diestrus. In 3A, the red fluorescent signal represents cytokeratin, a marker
for luminal epithelial cells, while in 3B the red signal is p63, a marker of myoepithelial cells, and all nuclei are stained with DAPI (4006).
doi:10.1371/journal.pone.0011768.g001
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cells for citrullination only during diestrus and EGF can
stimulate histone H3 citrullination
The expression pattern and functional role of PAD catalyzed
citrullination in mammary tissue has not previously been
examined. To address this issue, canine mammary tissue sections
from anestrus, estrus/early diestrus, and late diestrus were assessed
by western blot analysis with an antibody that recognizes
citrullinated proteins (anti-pan-citrulline antibody) as previously
described [21]. Pan-citrulline western blots detected three strong
bands corresponding to 33, 15, and 10 kDa in diestrus canine
mammary tissue samples while citrullinated proteins were not
detected (or weakly detected) at other stages (Figure 4B). Based on
their molecular weights, we speculate that the 33 kDa band is
nucelophosmin, a known PAD substrate, and that the 10 and
15 kDa bands are likely histone H3 and H4. To further validate
that the lower molecular weight proteins from the diestrus sample
were histones, we citrullinated bulk histones using purified PAD2
and found that similarly sized histone bands at 10 and 15 kDa
were observed (Figure 4B, control).
In order to establish where PAD-mediated citrullination was
occurring within mammary tissue, sections from anestrus, estrus/
early diestrus and late diestrus were subject to IF and interrogated
with the pan-citrulline antibody. As expected, only the late diestrus
samples showed fluorescent pan-citrulline signal. Further, we also
found that this signal was primarily limited to the nucleus of a
subset of epithelial cells (Figure 4C). Our finding that mammary
gland epithelial cell histones appear to be a target for citrullination
at diestrus raises the exciting possibility that one function of PADs
in mammary tissue is to regulate gene activity via histone
citrullination. To further test this hypothesis, western blots of
diestrus mammary tissue samples were probed with the H3 cit 2-8-
17, H3 cit 26, and H4 cit 3 site-specific anti-citrullinated histone
antibodies. Purified PAD2 in vitro citrullinated CMT25 cell
histones were included as a positive control. Interestingly, we
found that citrullination was limited to the arginine residues at 2,
8, and 17 on the histone H3 tail suggesting that these residues are
the primary targets of PAD activity in mammary epithelial cells
(Figure 4D). Next we examined the ability of EGF, presumably
acting via PAD2, to induce citrullination of histone H3 tails by
western blot. EGF treated CMT25 cells show an increase
citrullination of histone 3 tail residues 2, 8, and 17 similar to
what we found in mammary tissue suggesting a role for EGF in not
only PAD2 expression, but also activity (Figure 4E). Given that
PAD2 activity is restricted to diestrus in vivo, the main secretory
phase of the estrous cycle, our findings support the hypothesis that
PAD2 may play a role in the regulation of the expression of
lactation related genes in mammary epithelial cells via histone
citrullination, and we are currently directly testing this hypothesis.
Discussion
Canine mammary glands undergo dramatic molecular and
morphological reorganization during the estrous cycle to convert
mammary tissue to an active secretory gland. Specific stages of the
estrous cycle are defined by morphologic and molecular signatures
such as generalized edema and proliferation during estrus/early
diestrus, production of lactation related gene products during late
diestrus and apoptosis during involution towards the metestrus to
anestrus crossover. These dramatic cellular transformations are
clearly orchestrated, in part, by sex steroid hormones. However,
the downstream targets and molecular mechanisms catalyzed by
these hormones that effect cellular reorganization are poorly
understood. Given that PADs are regulated by E2 in rodents and
that citrullination of target proteins by PADs has been found to
cause dramatic reorganization in both the cytoplasm and nuclear
architecture, these enzymes are strong candidates for mediating
hormonal changes throughout the canine estrous cycle.
IHC and IF studies of canine mammary tissue illustrate that the
patterns and intensity of PAD2 expression change over the estrous
cycle. For example, in estrus/early diestrus PAD2 expression is
sparse, yet distinct, in cells within the alveolar end units. During
diestrus, PAD2 expression is more widespread potentially
indicating that, although expression is initiated during estrus,
expression expands to additional epithelial cells throughout
diestrus. Given this expression pattern, we hypothesize that
PAD2 may possibly be involved in converting the mammary
gland to an active secretory organ. Studies in rodent models have
also suggested that PAD2 may be involved in a secretory function
in the uterus [22].
Figure 2. PAD2 mRNA and protein are differentially expressed across the canine estrous cycle with highest levels detected during
late diestrus. (A) RNA was purified from canine mammary tissue samples, reverse transcribed and resulting cDNA was used in qPCR reactions with
intron spanning primers specific for the 75 kDa isoform of PAD2 and RPS5, a characterized canine reference gene. All values are normalized to
anestrus samples and bars represent the means 6 SEM. Means were separated by one-way ANOVA using Tukey’s HSD and the letters a and b
represent significant differences (P,0.01). (B) Canine mammary tissue samples from anestrus, estrus/early diestrus and late diestrus were subject to
SDS-PAGE and probed with an anti-PAD2 antibody which detected a 75 kDa band, the estimated molecular weight of PAD2.
doi:10.1371/journal.pone.0011768.g002
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estrus/early diestrus and late diestrus indicate that expression of
PAD2 increases from estrus/early diestrus through late diestrus
suggesting that hormonal changes during the estrus cycle may be
involved in regulation of PAD2 expression. Thus, the ovarian sex
steroids E2 and P4 would be appear to be the most likely
candidates to regulate PAD2 expression in vivo, however our
results using the CMT25 cell line indicate that E2 and P4 are likely
not directly involved in regulation of PAD2 in vitro. Although the
CMT cell lines are derived from canine mammary epithelial cells,
their ability to respond to E2 and P4 is currently unknown and can
therefore not be conclusively ruled out in contributing to PAD2
expression. In contrast, EGF can directly increase PAD2
expression in vitro. Growth factors are believed to establish
auto-, para- and juxtacrine loops that are thought to augment and
amplify initial steroid hormone signals. Therefore, the regulation
of PAD2 expression in vivo is likely multifactoral. Interestingly,
EGF receptor levels in canine mammary tissue increase from
Figure 3. Treatment of the canine mammary tumor (CMT25) cell line with EGF results in an increase in PAD2 expression levels. (A)
Western blot illustrating that only EGF treatment increases PAD2 protein levels with b-actin shown as a loading control. Densitometry measurements
quantified treatment groups compared to vehicle treated control in three independent experiments and bars represent the means 6 SEM. * indicates
a statistically significant difference from other treatments (P,0.01) (B) Quantitative PCR analysis revealed elevated PAD2 transcript levels in CMT25
cells treated with EGF compared to vehicle treated control and * indicates a statistically difference from the other treatments (P,0.05).
doi:10.1371/journal.pone.0011768.g003
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observed increase in PAD2 expression [23]. Additionally, we show
that there is increased citrullination of CMT25 histone 3 tail
arginine residues 2, 8, and 17 after EGF treatment, further
supporting our hypothesis that histones are targets for PAD2.
Induction of citrullination by EGF has not previously been
reported and our lab is currently working to understand the up-
and downstream signaling pathways that mediate this increase in
PAD2 and its catalytic activity.
One unexpected result from our IHC and IF experiments is
that, in addition to expected cytoplasmic and peri-nuclear
localization, PAD2 is also detected in the nucleus of mammary
Figure 4. PAD2 association with histone citrullination. (A) PAD2 is detected in the nucleus and cytoplasm of mammary epithelial. PAD2
expression is shown in green and nuclear DAPI stain is in blue with white arrows denoting punctuate PAD2 staining in euchromatic nuclear regions
(10006). (B) PADs target histones from mammary gland epithelial cells for citrullination and this activity is restricted to late diestrus. Canine mammary
tissue samples from anestrus, estrus/early diestrus and late diestrus were examined by SDS-PAGE and probed with an anti-pan-citrulline antibody. (C)
Late diestrus mammary tissue sections were subject to a modified IF protocol using the anti-pan-citrulline antibody. The panel shows pan-citrulline
staining in green and nuclear DAPI stain in blue (10006). (D) Late diestrus canine mammary tissue samples and in vitro citrullinated CMT25 histones
(as a positive control) were examined by SDS-PAGE and probed with the histone tail citrullination specific antibodies H3cit 2-8-17, H3cit 26, or H4cit3 .
(E) Western blot analysis of CMT25 cells treated with EGF for 24 hours show increased histone tail citrullination using a H3 cit 2-8-17 specific antibody.
Equal loading was confirmed using a mouse histone 3 antibody.
doi:10.1371/journal.pone.0011768.g004
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tissues is thought to be limited to the cytoplasm. Thus, our finding
suggests that PAD2 localization and function may be dependent to
some degree upon the cell type in which it is expressed, and that
the role and targets of PAD2 in the mammary gland may be
different from those of other tissue types. Presently, studies are
underway to determine the possible mechanism by which PAD2
translocates to the cell nucleus in mammary epithelial cells.
Given that no previous studies have documented PAD
expression in the mammary gland nor have previous reports
demonstrated that PAD-mediated citrullination occurs in mam-
mary tissue, we believe that this study provides significant new
insight into PAD biology. For example, our finding that PAD-
mediated citrullination in mammary tissue appears to be restricted
to epithelial cells during a distinct stage of the estrous cycle and
limited to a small subset of targets (likely histones and
nucleophosmin) suggests that PAD activity is likely facilitating a
specific event during diestrus. Further, the observation that histone
citrullination correlates with PAD2 expression in mammary
epithelium at diestrus and that a fraction of PAD2 is nuclear in
these cells, raises the possibility that PAD2 may play a role
regulating gene activity in the mammary epithelium. Currently,
we are testing whether the observed histone citrullination activity
is directly regulated by PAD2 or is possibly indirectly regulated by
PAD2 via crosstalk with PAD4. Subsequent findings directly
demonstrating that PADs regulate gene activity in the mammary
gland epithelium would likely lead to the identification of new
regulatory pathways important for mammary function.
Supporting Information
Figure S1 Immunohistochemitry in canine mammary with
PAD-4. (A) As an IHC control, anestrus, estrus/early diestrus,
and late diestrus mammary tissue sections were probed with equal
concentration of rabbit IgG (compared to anti-PAD2) and
counterstained with hematoxylin. (B) Anestrus, estrus/early
diestrus, and late diestrus mammary tissue sections were are also
probed with an anti-PAD4 antibody, and opposite of PAD2
staining, showed highest PAD4 levels in anestrus with lowest
staining during late diestrus.
Found at: doi:10.1371/journal.pone.0011768.s001 (2.96 MB TIF)
Figure S2 The PAD2 antibody is not cross reactive with other
PAD family members. Mammalian expression plasmids contain-
ing the cDNA for human PADs 1, 2, 3, and 4 were transiently
transfected into human embryonic kidney 293 cells. After
24 hours, cells were harvested and overexpression lysates run on
a western blot probed with anti-PAD2.
Found at: doi:10.1371/journal.pone.0011768.s002 (0.12 MB TIF)
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